Teva and Mount Sinai Health System pursue
new models to reduce cost and complexity of care
Today, two leading private sector groups announced a partnership
to create scalable solutions to improve patient and health system
care for Multiple Chronic Conditions.
The initiative was announced to an audience of public health
leaders at the World Economic Forum’s (WEF) Sustainable Development
Impact Summit. The meeting, which formed a part of the Summit, was
convened to advocate for action to address Multiple Chronic
Conditions (MCC), an emerging and unaddressed global health threat.
MCC are defined by the presence of two or more chronic conditions
in a patient, representing a growing pain point for families and
society. Currently, one in three adults globally, and two in three
adults over the age of 65, suffer from two or more chronic
conditions.
MCCs are a global problem spanning multiple disease areas and
affecting patients, communities and healthcare systems in different
ways. The top conditions contributing to mortality and morbidity in
high-income countries include ischemic heart disease (IHD), stroke,
lung cancer, depression, diabetes and back and neck pain. In low-
and middle-income countries, the top diseases include IHD, stroke,
diabetes, and depression, as well as communicable diseases, such as
diarrhea, HIV and tuberculosis.
TEVA Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), the
world’s largest generic drug company, and Mount Sinai Health
System, one of the largest hospital groups in the United States,
aim to gain new data and insights into interventions that can meet
the needs of people with MCC. One pillar of this effort is a
regional pilot program at Mount Sinai’s Arnhold Institute for
Global Health in New York, which will design and evaluate a
patient-centered, integrated approach and ultimately, adapt it for
delivery to larger patient populations. Dr. Sandeep Kishore, MD,
PhD, Associate Director of the Arnhold Institute for Global Health,
leads work on global multiple chronic conditions.
A new report introduced at the meeting, Multiple Chronic
Conditions: The Global State, quantifies the health, economic and
personal burden weighing on patients, families and healthcare
systems. The report found that with each additional chronic
condition, healthcare costs more than double, so that treating a
patient with four chronic conditions could cost as much as 16 times
more than a patient with only one condition. It also revealed that
multiple chronic conditions also greatly reduces the patient’s
ability to comply with medication, increases the likelihood of
depressive symptoms and greatly increases the care burden on
families and health facilities.
The report also found that focusing care around the patient’s
overall health and wellbeing as opposed to treating individual
diseases in isolation, and by employing better technologies, health
systems can actually reduce the cost of care while improving the
quality of life for patients. Proposed changes include
re-introducing the concept of a family doctor, since the family
doctor can coordinate care, creating patient-focused teams of
specialists who work better together, improving opportunities for
home care, and creating combination therapy drugs that reduce the
need for patients to take a large number of different medicines and
improve adherence.
The meeting presented the global scope of MCC by assessing both
the financial burden and the toll on human suffering. Experts
discussed how to build a common understanding of challenges and
gaps in current treatment models, and how to advance near and
long-term solutions. Participants emphasized the importance of
coordinated care models centered around the patient, in which all
of a patient’s chronic conditions are managed comprehensively,
rather than as discrete problems. They also explained the
usefulness of digital platforms that integrate treatment as a way
to alleviate the burden on patients, families and the healthcare
system. They warned about escalating costs and deteriorating
patient quality of life as the current MCC population ages, and as
developing countries face the double burden of long-term
communicable diseases alongside chronic conditions.
“All signs in our research support the fact that as the current
population ages, and more young adults are diagnosed with multiple
chronic conditions, the cost and complexity for healthcare systems
will rise exponentially,” said Derek Yach, MBChB MPH and co-author
of Multiple Chronic Conditions: The Global State. “The global scale
of this growing public health issue warrants a much more robust,
well-integrated response. Now is the time for action and pragmatic
solutions that will help alleviate pressure on governments,
providers, patients and their families.”
“While the personal challenges may differ, the mental, social
and financial strain of multiple chronic conditions on patients and
their families is universal,” said Iris Beck Codner, Group
Executive Vice President of Teva Pharmaceuticals. “We hope this
effort will shed light on the unique pressures weighing on patients
and the potential for centering treatment on the patient versus
individual conditions to help them live better and longer
lives.”
"In low-income and underserved communities, nearly one in every
two patients suffer from multiple chronic conditions," said
Prabhjot Singh, MD, PhD, Director of The Arnhold Institute for
Global Health and Chair, Department of Health System Design and
Global Health, Mount Sinai Health System. "Health systems must
do a better job of caring for these patients in ways that
incorporate the full context of their lives. Our goal at Mount
Sinai is to develop better methods and care models to change the
trajectory of outcomes for these patients in New York and around
the world, and ultimately drive impact to keep patients healthier
for longer.”
The Summit discussion and Multiple Chronic Conditions report
reviewed opportunities to reduce the toll from MCC. Potential areas
for exploration in public-private partnerships include:
- Cross-Condition Management:
Opportunities include innovative primary care models that
coordinate treatment of different conditions across providers, as
well as guidelines to help providers assess and treat patients with
MCC by using symptom-based algorithms.
- Medication Regimen
Simplification: Adapting dosage plans so patients have fewer
pills to remember – and take – each day, as a way to increase
control of chronic conditions. For example, providers can improve
the patient’s medication adherence by prescribing fixed-dose
combination medicines, which combine multiple medications in a
single pill, and with digital compliance technology, such as pills
with sensors that generate data the medical team can monitor.
- Technology-based Solutions:
Making care more accessible and personalized through advancements
such as telemedicine and remote monitoring to provide on-demand
treatment, as well as cognitive computing to derive insights into
medication interactions.
To learn more about Multiple Chronic Conditions: Global State,
please visit, http://tevapharm.com/files/docs/Teva_MCC_Report.pdf.
For more information on Teva’s Corporate Social Responsibility
efforts, please visit:
http://www.tevapharm.com/corporate_responsibility/.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200
million patients in over 60 markets every day. Headquartered in
Israel, Teva is the world’s largest generic medicines producer,
leveraging its portfolio of more than 1,800 molecules to produce a
wide range of generic products in nearly every therapeutic area. In
specialty medicines, Teva has the world-leading treatment for
multiple sclerosis as well as late-stage development programs for
other disorders of the central nervous system, including movement
disorders, migraine, pain and neurodegenerative conditions, as well
as a broad portfolio of respiratory products. Teva is leveraging
its generics and specialty capabilities in order to seek new ways
of addressing unmet patient needs by combining drug development
with devices, services and technologies. Teva's net revenues in
2016 were $21.9 billion. For more information, visit
www.tevapharm.com.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest
integrated delivery system encompassing seven hospital campuses, a
leading medical school, and a vast network of ambulatory practices
throughout the greater New York region. Mount Sinai’s vision is to
produce the safest care, the highest quality, the highest
satisfaction, the best access and the best value of any health
system in the nation. The System includes approximately 7,100
primary and specialty care physicians; 10 joint-venture ambulatory
surgery centers; more than 140 ambulatory practices throughout the
five boroughs of New York City, Westchester, Long Island, and
Florida; and 31 affiliated community health centers. Physicians are
affiliated with the renowned Icahn School of Medicine at Mount
Sinai, which is ranked among the highest in the nation in National
Institutes of Health funding per investigator. The Mount Sinai
Hospital is ranked No. 18 on U.S. News & World Report’s “Honor
Roll” of top U.S. hospitals; it is one of the nation’s top 20
hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology,
Gastroenterology/GI Surgery, Geriatrics, Nephrology, and
Neurology/Neurosurgery, and in the top 50 in four other specialties
in the 2017-2018 “Best Hospitals” issue. Mount Sinai’s Kravis
Children’s Hospital also is ranked in six out of ten pediatric
specialties by U.S. News & World Report. The New York Eye and
Ear Infirmary of Mount Sinai is ranked 12th nationally for
Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai
Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked
regionally. For more information, visit http://www.mountsinai.org/,
or find Mount Sinai on Facebook, Twitter and YouTube.
Cautionary Statements Regarding Forward-Looking
Information:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding the potential benefits and commercialization of
Fremanezumab, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: the uncertainty of
commercial success of Fremanezumab; challenges inherent in product
research and development, including uncertainty of obtaining
regulatory approvals; our specialty medicines business, including:
competition for our specialty products, especially Copaxone®, our
leading medicine, which faces competition from existing and
potential additional generic versions and orally-administered
alternatives; our ability to achieve expected results from
investments in our product pipeline; competition from companies
with greater resources and capabilities; and the effectiveness of
our patents and other measures to protect our intellectual property
rights; our business and operations in general, including: our
ability to develop and commercialize additional pharmaceutical
products; manufacturing or quality control problems, which may
damage our reputation for quality production and require costly
remediation; interruptions in our supply chain; disruptions of our
or third party information technology systems or breaches of our
data security; the restructuring of our manufacturing network,
including potential related labor unrest; the impact of continuing
consolidation of our distributors and customers; and variations in
patent laws that may adversely affect our ability to manufacture
our products; compliance, regulatory and litigation matters,
including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; potential additional adverse
consequences following our resolution with the U.S. government of
our FCPA investigation; governmental investigations into sales and
marketing practices; potential liability for sales of generic
products prior to a final resolution of outstanding patent
litigation; product liability claims; increased government scrutiny
of our patent settlement agreements; failure to comply with complex
Medicare and Medicaid reporting and payment obligations; and
environmental risks; and other factors discussed in our Annual
Report on Form 20-F for the year ended December 31, 2016 (“Annual
Report”), including in the section captioned “Risk Factors,” and in
our other filings with the U.S. Securities and Exchange Commission,
which are available at www.sec.gov and www.tevapharm.com.
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170918005801/en/
Teva Pharmaceutical Industries Ltd.IR Contacts:Kevin C.
Mannix, United States, 215- 591-8912Ran Meir, United
States, 215-591-3033Tomer Amitai, Israel, 972 (3)
926-7656orPR Contacts:Iris Beck Codner, Israel, 972 (3)
926-7687Denise Bradley, United States, 215-591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024